Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Total revenues		$ 10,455	$ 422
Operating expenses:
Research and development	$ 23,264	17,291	14,048
General and administrative	10,751	9,075	9,352
Total operating expenses	34,015	26,366	23,400
Loss from operations	(34,015)	(15,911)	(22,978)
Total other income (expense), net	238	(319)	(785)
Consolidated net loss	(33,777)	(16,230)	(23,763)
Net loss attributable to noncontrolling interest in Pangu BioPharma Limited	9	6	160
Net loss attributable to aTyr Pharma, Inc.	$ (33,768)	$ (16,224)	$ (23,603)
Net loss per share, basic and diluted	$ (1.77)	$ (1.77)	$ (7.03)
Shares used in computing net loss per share, basic and diluted	19,080,878	9,160,269	3,355,600
License Revenues [Member]
Revenues:
Total revenues		$ 10,455	$ 422